SELLAS Life Sciences Group, Inc. — Director's Dealing 2011

Mar 18, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-03-15

Reporting Person: Khvorova Anastasia (Chief Science Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-03-15	Common Stock	A	43053	$0.00	Acquired	60559	Direct

Footnotes

F1: The Common Stock reported on this Form 4 represent restricted stock units with a contingent right to receive one share RXII common stock for each restricted stock unit and will be fully vested on March 23, 2011.